Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences and Merck & Co have signed an agreement through which Gilead will assume the lead role for the distribution of Atripla in 12 countries located primarily in Latin America and the Asia-Pacific region.
Subscribe to our email newsletter
Under the terms of the agreement, Gilead will assume the lead role in the registration, manufacturing and distribution of Atripla in Argentina, Australia, Chile, Hong Kong, Israel, Mexico, New Zealand, Russia, Taiwan, Thailand, Turkey and Uruguay.
The companies will share the revenues and costs associated with registering and distributing the product. Going forward, additional countries may be added to this new agreement by mutual consent.
Atripla is said to be the first once-daily single tablet regimen for HIV. It contains three HIV medicines: efavirenz, emtricitabine and tenofovir disoproxil fumarate.
Kevin Young, executive vice president of commercial operations at Gilead Sciences, said: “This new agreement reflects Gilead’s ongoing commitment to ensuring global access to the first and only single tablet regimen for the treatment of HIV.”